Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Prepare for a bounce this week
Best wishes everyone
Time for the train to ve the station
Oh no, so unfortunate, Reverse Split, devalue our hard- earned monies
(rwa3848) I'm certain that an RS is not a viable path to nasdaq because it will delay application approval. In addition, institutional investors rely more upon the stability of share structure for publicly listed companies for the arbitrage of financial capital creation than they do quarterly incidentals
I like you comment. Certainly, reasonable, true. Let's hope for the best this week.
GO IQST$$$$
Going to run hard just matter of time $$$IQST$$$$
YEAP
(Aug 8) Shares of Telecom Firm Higher on Planned Strategic Announcement
By: Tomas Ronolski - AllPennyStocks.com News
Thursday, August 8, 2024
- As it prepares for its Nasdaq uplisting, shares of this telecom firm are on the upswing on news of a planned strategic acquisition.
-- U.S.-based, multinational telecommunications and technology company iQSTEL Inc. (OTC:IQST) made a major announcement in a press release today that has shares trading higher. iQSTEL recently announced plans to expand sales to $1 billion by fiscal year 2027. The firm released an extensive business plan earlier this week that detailed key specific steps to reaching that goal.
-- Highlights will be released at an upcoming conference
-- and include a targeted strategic acquisition expected to add $200 million to $300 million in annual sales,
-- a $30 million raise in conjunction with the strategic acquisition
-- and Nasdaq uplisting.
Additionally, organic sales are expected to double existing and acquired sales.
In morning trade, shares were up around 5 percent.
"Solid company growing and with a good vision of the changing market place. They will be a much bigger player"
Yeap. The best is yet to come
Amazingly Bullish! Confidently going up steadily with innovation
-------------
Message in reply to: Colonel_Mustard
Love the rebranding beyond the original hydrogen water drink as well as the addition of three new health and sports/workout beverages, including a K-Cup coffee!
Matina has a great future. Buy and hold patiently.
Solid move, confidently going upward.
Yes, thanks the IQSTEL management team for its super daily tasks, transparency, knowledge, resilience (especially during the pandemic), good vision and commerce skills toward the future. We have been waiting for many years patiently to profitability and wealth. The best is yet to come.
Has LTNC ever had penny ?
Awesome move the last few days. I am sooooo happy to HOLD this for a few years.
Patience really pay ! Congratulations everyone. The best is yet to come. Can anyone summarize
the content of that conference on X ? Million people there could be interested on LTNC
Good news for MTNB
"We project that the market for MAT2203 in the treatment of invasive aspergillosis in patients with limited treatment options could reach peak sales in the U.S. alone of over $400 million annually..."
Hell yeah :) This is the BEST week we ever had lately.
HOLD ON TIGHT friends. $$$$$ IQST $$$$$ is growing fast
with large profits. Trust IQST and the CEO is very transparent.
There is NO OTHER WAY, only one way to go up up and away.
The train has left the station. Hold on tight...to da moon.
Think of 5 years from now. We will be very happy to....retire comfortably.
Hell yeah, big move!
iQSTEL management confirms April 1(st) as the target date for closing the acquisition.
iQSTEL CEO Leandro Iglesias said, "We have been consistently breaking one record after another quarter after quarter since Q3 last year. This is an important milestone for IQSTEL because we announced profitability in Q3-FY2023. We are very optimistic this trend will continue for Q2 FY-2024 and beyond enhanced further by the pending acquisition closing of QXTEL."
BUY AND HOLD for many years :) Soooo happy, patience and patience is rewarding.
GOD BLESS IQST and hard-working CEO and Team.
Let us dream of $5 in 5 years ! Let us all retire comfortably with our darling IQST. Thanks IQST team for transparency & positiveness
throughout the pandemic and now growing strategically faster. Comforfably hope for the best is yet to come
--------------
Re: tooshort009 post# 50415
Post# of 50431
$5 you kidding I'll be happy with a dollar at this point. More like $5 in 5 years
Can't wait for IQST to GROW bigger in values. We are sitting patiently all those years.
Congratulations for those who BUY LOW. We are going up the ladder, step by step.
IQST is doing well duing the pandemic, will be mucho better during Trump era.
We are ready for good news coming !
Happy New Year of the Dragon, where IQST will fly higher than $1 for sure, we all have been patiently HOLD and BUY for many years. A solid company with headquarter in Houston Texas a good state with law and order. The legendary Dragon is a symbol of strength, power, intelligence, revolution, change! Time for IQST to fly high in 2024! God Bless IQST
Hold on tight to your shares.
Patience will shoot us far
Happy New Year everyone
Hell yeah hihi I have always trust IQST too
Love it ! The train is leaving the old rusty station
Go fast IQST to da moon. Expect $1 this year !
Really, trust in IQST, headquarter in Texas USA.
It is getting more exciting a, Thank IQST team!
IQST will be hot in 2024. Patience is rewarding
Stay strong, stay cool. IQST is a trusted Stock with solid growth.
-----
iQSTEL on Thursday said revenue for 2023 increased by 50% over 2022 to $140 million delivering $0.81 per share compared to $0.57 per share the previous year. The company said its gross margin also continues to grow with the company reporting a gross margin increase in Q4-2023 after the operating income turned positive ahead of schedule in Q3-2023. Management expects revenue and margins to continue growing rapidly in 2024.
$$$IQST$$$$ Watch out for the train coming fast at year end
Merry Christmas everyone. The best is yet to come.
Biotech Catches Massive Premarket Bid
By: Tomas Ronolski - AllPennyStocks.com News
Wednesday, October 11, 2023
A New Jersey-based biotech company is catching a serious premarket bid this morning following a press release detailing the company’s announcement that they completed clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei, a fluconazole inherited resistant fungal pathogen, following treatment with the company’s MAT2203.
Traders immediately got excited about this news, as shares of Matinas Biopharma Holdings Inc. (NYSE American: MTNB) are currently bid up at $0.2693/share (+73.74% implied open for sellers) at the time of writing. This should be an exciting session for this micro cap!
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
Copyright © 2023 AllPennyStocks.com. All rights reserved.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
Matinas’ lead which although highly potent, can be associated with significant toxicity. Matinas’ LNC platform provides oral delivery of amphotericin B without the significant nephrotoxicity otherwise associated with IV-delivered formulations. MAT2203 also allows for safe, longer-term use outside of a hospital setting, which could have substantial favorable pharmacoeconomic impact. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 will be further evaluated as an oral step-down monotherapy treatment following IV AMB in a single pivotal Phase 3 study in the treatment of aspergillosis in persons with limited treatment options who are unable to be treated with azoles for reasons related to drug-drug interactions, resistance or for whom these antifungal agents are unable to be used for other clinical reasons.
In addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can potentially provide solutions to many of the challenges standing in the way of achieving safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargos such as RNAi, antisense oligonucleotides, and vaccines. The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred next-generation orally available intracellular drug delivery platform. For more information, please visit www.matinasbiopharma.com.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
CONFERENCE TODAY Oct.12 and THURSDAY Oct. 19 next week
September 28 2023 - 07:00AM
GlobeNewswire Inc.
Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
Dawson James Small Cap Growth Conference being held Thursday, October 12 at the Wyndham Grand Harborside Hotel in Jupiter, Fla. The presentation is scheduled for 3:30 p.m. Eastern time.
The ThinkEquity Conference being held Thursday, October 19 at the Mandarin Oriental Hotel in New York City.
The presentation is scheduled for 11:00 a.m. Eastern time.
A webcast of the presentation at the Dawson James Small Cap Growth Conference will be available live on the IR Calendar page of the Investors section of the company’s website. The webcast will be archived for 90 days. Institutional investors interested in arranging a meeting with Matinas BioPharma management, please contact Jody Cain at LHA investor relations at jcain@lhai.com.
Try to HOLD. This is a good stock.
Take a look: who are the financial institution
large shareholders of MTNB?
Largest shareholders include
Vanguard Group Inc, VTSMX
Vanguard Total Stock Market Index Fund Investor Shares,
Sargent Investment Group, LLC, BlackRock Inc.,
VEXMX - Vanguard Extended Market Index Fund Investor Shares,
Geode Capital Management, Llc,
Arkadios Wealth Advisors,
Neville Rodie & Shaw Inc,
FSMAX - Fidelity ...
2 CONFERENCES IN OCTOBER 2023
YEAH BIG move !
I was lucky to add 7000 shares at .14 ❤️😃👍
I WILL HOLD TILL OVER $3
A small and promising company
Best wishes everyone! Trust in MTNB !
Matinas BioPharma to Present at Two Investment Conferences in October 2023
September 28, 2023 7:00am EDT
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
Dawson James Small Cap Growth Conference being held Thursday, October 12 at the Wyndham Grand Harborside Hotel in Jupiter, Fla. The presentation is scheduled for 3:30 p.m. Eastern time.
The ThinkEquity Conference being held Thursday, October 19 at the Mandarin Oriental Hotel in New York City. The presentation is scheduled for 11:00 a.m. Eastern time.
A webcast of the presentation at the Dawson James Small Cap Growth Conference will be available live on the IR Calendar page of the Investors section of the company’s website. The webcast will be archived for 90 days.
Institutional investors interested in arranging a meeting with Matinas BioPharma management, please contact Jody Cain at LHA investor relations at jcain@lhai.com.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
Matinas’ lead LNC-based therapy is MAT2203, an oral formulation of the broad-spectrum antifungal drug amphotericin B, which although highly potent, can be associated with significant toxicity. Matinas’ LNC platform provides oral delivery of amphotericin B without the significant nephrotoxicity otherwise associated with IV-delivered formulations. MAT2203 also allows for safe, longer-term use outside of a hospital setting, which could have substantial favorable pharmacoeconomic impact. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in cryptococcal meningitis, meeting its primary endpoint and achieving robust survival.
MAT2203 will be further evaluated as an oral step-down monotherapy treatment following IV AMB in a single pivotal Phase 3 study in the treatment of aspergillosis in persons with limited treatment options who are unable to be treated with azoles for reasons related to drug-drug interactions, resistance or for whom these antifungal agents are unable to be used for other clinical reasons.
In addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can potentially provide solutions to many of the challenges standing in the way of achieving safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargos such as RNAi, antisense oligonucleotides, and vaccines. The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred next-generation orally available intracellular drug delivery platform. For more information, please visit www.matinasbiopharma.com.
(...)
Investor Contact
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Looking for a bright future for MTNB$$: MAT 2203 as a viable drug, and Matinas as a promising company, and could garner interest from potential partners.
-------------
Matinas deserves congratulations for getting publication of the ENACT trial results in a per reviewed journal. Unfortunately, the position taken by the FDA regarding a Phase 3 trial for MAT 2203 for invasive fungal infections has made to impractical for Matinas to conduct such a study. In light of this setback, I think it would make sense for Matinas to go back to the original plan—a Phase 3 pivotal trial for CM. Approval for this indication would validate MAT 2203 as a viable drug, and Matinas as a promising company, and could garner interest from potential partners.
While sales for CM would likely be modest, MAT 2203 could possibly be used off label for other indications that would help to validate the use of MAT 2203 for other IFI (along with the LPAD pathway).
Matinas sorely needs a “W,” and getting approval of MAT 2203 for some indication could be the win it needs to get positive recognition and possible funding.
LM
Martini👍️ ! The train is about to leave the station, FAST !
Next week will be very interesting. Cheers everyone!
Surprises will come anytime. Martini 😀♥️
Trust in IQSTEL. The best is yet to come !
----------------------
iQSTEL Inc. (OTC-QX: IQST) (www.iQSTEL.com) is a US-based, multinational publicly listed company preparing for a Nasdaq up-listing with an FY2023 $120 million revenue forecast. iQSTEL's mission is to serve basic human needs in today's modern world by making the necessary tools accessible regardless of race, ethnicity, religion, socioeconomic status, or identity.
iQSTEL recognizes that in today's modern world, the pursuit of the human hierarchy of needs (physiological, safety, relationship, esteem and self-actualization) is marginalized without access to ubiquitous communications, the freedom of virtual banking, clean affordable mobility and information and content. iQSTEL has 4 Business Divisions delivering accessibly to the necessary tools in today's pursuit of basic human needs: Telecommunications, Fintech, Electric Vehicles and Metaverse.
- The Enhanced Telecommunications Services Division (Communications) includes VoIP, SMS, International Fiber-Optic, Proprietary Internet of Things (IoT), and a Proprietary Mobile Portability Blockchain Platform.
- The Fintech Division (Financial Freedom) includes remittances services, top up services, Master Card Debit Card, a US Bank Account (No SSN required), and a Mobile App.
- The Electric Vehicles (EV) Division (Mobility) offers Electric Motorcycles and plans to launch a Mid Speed Cars.
- The Artificial Intelligence (AI)-Enhanced Metaverse Division (information and content) includes an enriched and immersive white label proprietary AI-Enhanced Metaverse platform to access products, services, content, entertainment, information, customer support, and more in a virtual 3D interface.
The company continues to grow and expand its suite of products and services both organically and through mergers and acquisitions. iQSTEL has completed 10 acquisitions since June 2018 and continues to develop an active pipeline of potential future acquisitions.
iQSTEL Inc.
IR US Phone: 646-740-0907
IR Email: investors@iqstel.com
Contact Details
iQSTEL Inc.
+1 646-740-0907
investors@iqstel.com
Company Website
www.iqstel.com
Certainly good news for IQST$$$$
-----------
IQST - iQSTEL Signs $10M Term Sheet with LDA Capital to Back Nasdaq Uplist Plan
NEW YORK, NY -- September 13, 2023 -- InvestorsHub NewsWire -- iQSTEL Inc. (OTC-QX: IQST) today announced executing a term sheet with LDA Capital for $10 million as part of iQSTEL’s plan to uplist onto the Nasdaq Stock Market. iQSTEL is a high growth, enhanced telecommunications company making ubiquitous access to communications, news and general information, access to financial services and clean mobility available to all regardless of race, ethnicity, religion, socioeconomic status, or identity.
The company reported $93.2 million in revenue last year and is on track to meet or exceed its $120 million 2023 revenue forecast.
LDA Capital is an alternative investment group with expertise in complex, cross border transactions. The firm is led by an energetic, collaborative core leadership team with a proven track record that includes over 250 transactions in both private and public markets.
In conjunction with a new partnership, LDA Capital recently launched a $2 billion fund to make regionally specific investments in publicly listed and pre-IPO high-growth companies (Forbes).
The term sheet is not binding on the parties and the investment may only occur upon the execution of definitive documents, and there is no guarantee that this will happen. As stated in the term sheet, the $10 million investment is expected in two tranches. In advance of a Nasdaq uplisting, the first $5 million is expected to be placed in exchange for a 24 month bond.
iQSTEL plans to utilize the $5 million to expand its core telecommunications business by completing an acquisition that is expected to add disruptive innovation and positive financial fundamentals, to include revenue with positive net income. The second $5 million is expected to be placed in exchange for a second $5 million bond available following a successful uplisting to Nasdaq.
Management believes the company is currently undervalued and that the partnership with LDA Capital may bring new market wide visibility that in turn has the potential to elevate iQSTEL's market cap to be more in line with the company's underlying value.
If the investment is realized and an acquisition is accomplished, iQSTEL management believes that its share price has the potential to organically achieve the minimum price necessary to uplist to Nasdaq.
"We greatly appreciate the confidence LDA Capital has shown for iQSTEL's track record, management team, and business plan," said Leandro Iglesias, CEO of iQSTEL. "LDA Capital has an impressive history of successful investments that demonstrate extensive experience with international growth businesses. iQSTEL management believes the caliber of the investment team is far more important than the funds alone. We believe we could not ask for a better fit for iQSTEL's investment needs than LDA Capital. Together we are setting the table for a Nasdaq uplisting."
iQSTEL and LDA Capital are beginning a 30 day due diligence engagement as the first step toward an anticipated definitive investment agreement. iQSTEL has agreed not to solicit any competing offers during the due diligence period.
This press release does not constitute an offer of any securities for sale.
Tough times don't last, tough people do!
Hang in there friends. The best is yet to come.
----------------
Mon, August 14, 2023 at 11:41 AM PDT
NEW YORK, Aug. 14, 2023 /PRNewswire/ -- iQSTEL Inc. (OTCQX: IQST) (the "Company") today announced the Company published its Q2 2023 financial report on SEC Form 10Q. The report confirms the Company's previously announced preliminary results. Revenue in Q2 2023 was $32,824,829, compared with $23,699,716 for the three months ended June 30, 2022, reflecting an increase of 38.50%. The Company reported $57,491,358 year-to-date through the end of June. Management confirms the Company is on track to meet or exceed its $120 million 2023 revenue forecast.
In conjunction with the Q2 2023 financial report published today, iQSTEL CEO Leandro Iglesias has released a letter to shareholders. The letter is included in its entirety below.
Dear Shareholders:
On behalf of the iQSTEL Board of Directors and Management Team, I am proud of the Company's results year-to-date as reported in the current 10Q filing and believe the report is a clear indication that we are meeting, if not exceeding, our business plan objectives.
Our revenue is currently beating management expectations. We achieved $57.5M in revenue within the first half of this fiscal year. We are optimistic that the year-end results may exceed our $120 million annual revenue forecast. Historically, iQSTEL's revenues are higher in the second half of the year than the first.
iQSTEL's bottom-line performance is in keeping with our business plan. Q2 results are consistent with Q1. We maintained a monthly burn rate of approximately $54K (Net Loss of $320,466 in the first half of the year). The bottom-line results through the end of June 2023 are as expected by management and on track with management's plan to achieve profitability by the end of this year 2023. The initiatives underway to achieve profitability include the ongoing synergies we are realizing from the commercial combination of Etelix and SwissLink; the cost reductions in our platform and back-up services within Whisl and Smartbiz; the gross profit improvements coming from our QGlobal SMS services, and the operational improvements at IoTLabs.
Longer term, strategic contributions to both our top and bottom line will come from our new lines of business to include, for example, the anticipated full batch of our EV motorcycles we expect to sell in the second half of the year, and the profits we expect to begin realizing soon from our Fintech and Artificial Intelligence (AI)-Enhanced Metaverse operations.
At last, iQSTEL's merger and acquisition pipeline is robust and anticipated to also deliver major contributions to both the Company's top and bottom-line. iQSTEL's share price has enjoyed recent market-wide optimism allowing our share price to once again demonstrate an upward trend. At the same time management remains committed to its boycott against naked shorts and we keep working on our plans to up-list to Nasdaq, just waiting for the right time to do it.
Let me conclude with a grateful thank you to our long-term shareholders that have weathered a difficult market. It appears the storm may be clearing, though a few unknown hurdles likely remain ahead. I am optimistic that under more conducive market conditions, the yet unrealized value of iQSTEL can be seen more clearly. On behalf of the entire management team and our independent Board of Directors at iQSTEL, we continue to believe that the best is yet to come, and we are diligently working in accordance with that belief.
Sincerely
Leandro Iglesias
CEO and Chairman
iQSTEL, Inc.
About IQSTEL (updated August 2023):
iQSTEL Inc. (OTC-QX: IQST) (www.iQSTEL.com) is a US-based, multinational publicly listed company preparing for a Nasdaq up-listing with an FY2023 $120 million revenue forecast. iQSTEL's mission is to serve basic human needs in today's modern world by making the necessary tools accessible regardless of race, ethnicity, religion, socioeconomic status, or identity. iQSTEL recognizes that in today's modern world, the pursuit of the human hierarchy of needs (physiological, safety, relationship, esteem and self-actualization) is marginalized without access to ubiquitous communications, the freedom of virtual banking, clean affordable mobility and information and content. iQSTEL has 4 Business Divisions delivering accessibly to the necessary tools in today's pursuit of basic human needs: Telecommunications, Fintech, Electric Vehicles and Metaverse.
The Enhanced Telecommunications Services Division (Communications) includes VoIP, SMS, International Fiber-Optic, Proprietary Internet of Things (IoT), and a Proprietary Mobile Portability Blockchain Platform.
The Fintech Division (Financial Freedom) includes remittances services, top up services, Master Card Debit Card, a US Bank Account (No SSN required), and a Mobile App.
The Electric Vehicles (EV) Division (Mobility) offers Electric Motorcycles and plans to launch a Mid Speed Cars.
The Artificial Intelligence (AI)-Enhanced Metaverse Division (information and content) includes an enriched and immersive white label proprietary AI-Enhanced Metaverse platform to access products, services, content, entertainment, information, customer support, and more in a virtual 3D interface.
The company continues to grow and expand its suite of products and services both organically and through mergers and acquisitions. iQSTEL has completed 10 acquisitions since June 2018 and continues to develop an active pipeline of potential future acquisitions.
Safe Harbor Statement: Statements in this news release may be "forward-looking statements". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and iQSTEL Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
iQSTEL Inc.
IR US Phone: 646-740-0907
IR Email: investors@iqstel.com
Contact Details
iQSTEL Inc.
+1 646-740-0907
investors@iqstel.com
Company Website
iQSTEL - Publicly Listed Company: IQST
Looks amazing. Stair stepping to heaven baby. In 2 more weeks, we have earnings.
Hell yeah, long and strong !
Five bucks and beyond. Hell yeah ! Hang on strong friends
Add 4000 shares today. Going up again soon
Trust in our God-Bless IQST
Agree, IQST still way under valued !
Only .31. Next week, it should be .40
inching up steadily to .60 in July.
I could be over $1 in August. Let us dream.
IQST Stock Price Forecast. Should You Buy IQST?
https://stockinvest.us › stock › IQST
iQSTEL Stock Forecast: up to 18.986 USD! - IQST Stock Price ...
iQSTEL Inc quote is equal to 0.225 USD at 2023-07-18. Based on our forecasts, a long-term increase is expected, the "IQST" stock price prognosis for 2028-07-07 is 47.712 USD. With a 5-year investment, the revenue is expected to be around +21105.4%. Your current $100 investment may be up to $21205.4 in 2028.
Epazz, Inc. (OTC Pink: EPAZ) Tokens, Funding for over $2 million in Revenue, and Patent on AI Smart Battery Tech.
July 19 2023 - 05:49AM
InvestorsHub NewsWire
Epazz, Inc. (OTC Pink: EPAZ) Tokens, Funding for over $2 million in Revenue, and Patent on AI Smart Battery Tech.
Miami, FL -- July 19, 2023 -- InvestorsHub NewsWire – EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on Epazz, Inc. (OTC Pink: EPAZ).
Epazz, Inc. (OTC Pink: EPAZ) a mission-critical provider of drone technology, blockchain cryptocurrency mobile apps and cloud-based business software solutions, announced today that CryObo Technology would help farmers tokenize their crops through the issuance of NFT tokens in order to earn extra revenue.
Epazz, Inc. (OTC Pink: EPAZ) also recently announced that ZenaDrone has secured asset-based funding for the initial manufacturing and deployment of 20 ZenaDrone 1000s for services in Ireland to establish Drone as a Service (DaaS) operations. The company estimates that each deployed drone can generate over $100,000 per year.
Epazz, Inc. (OTC Pink: EPAZ) also recently announced today the company's subsidiary, Galaxy Batteries, Inc., has filed its first patent on artificial intelligence smart battery technology.
The recent court decision in favor of Ripple allows US Farmers to take advantage of CrybObo technology. Users of CrybObo will not need to file a registration statement for their tokens. The company will issue tokens for customers in accordance of the Court Decision. The company has been working on CryObo software which enables the tokenization of farm crops and produce. It allows farmers to raise capital immediately based on achieving future milestones and lets token holders evaluate the earned income of the token. It will enable industries to gain additional funding to spend on crop production. Tokenization of farm produce through CryObo Technology can help food security by providing farmers the additional funding to invest in improving crop and farm practices.
With the help of the ZenaDrone 1000 technology, the unmanned aerial vehicle can scan the field and record the accurate and actual health of the crops so farmers can monitor and more accurately predict potential harvest yield. In addition, it will allow farmers to make potential adjustments to irrigation, fertilization, and weed control during the growing season.
The NFT Tokens expand the market, and provide the opportunity to reach farm owners, plantation associations, and agricultural business investors. Token holders will get a share in the income generated from the tokenization of crop production and produce.
Epazz CryObo technology will also use solar power for sustainable Bitcoin mining and NFT tokens for farmland tokenization.
The Stock had a double bottom on July 5th and 6h at .0038. If that holds, the stock could bounce back over a penny and to its March 2023 highs of .0225. Keep EPAZZ, Inc. (OTC Pink: EPAZ) on your radar of drone technology stocks along with Amazon.com (NASDAQ: AMZN), EHang Holdings (NYSE: EH), Kratos Defense & Security Solutions (NASDAQ: KTOS), AeroVironment (NYSE: AVAV) Boeing Co. (NYSE: BA), Joby Aviation (NYSE: JOBY) and Northrop Grumman (NYSE: NOC)
We currently have invitations out for many companies to present on our conference including:
American International Holdings Corp. (OTC Pink: AMIH)
Good Vibrations Shoes, Inc. (OTC Pink: GVSI)
Northwest Biotherapeutics (OTCQB: NWBO)
Mullen Automotive, Inc. (NASDAQ: MULN)
About Epazz, Inc. (www.epazz.com)
Epazz Inc. is a provider of blockchain apps and a cloud-based software company specializing in providing customized cloud applications to the corporate world, higher-education institutions, and the public sector. Epazz BoxesOS™ v3.0 is a complete web-based software package for small- to mid-size businesses, Fortune 500 enterprises, government agencies and higher education institutions. BoxesOS provides many of the web-based applications organizations would otherwise need to purchase separately. Epazz's other products include K9Sky.com kennel software and the Provitrac applicant tracking system.
About CryObo Inc.
CryObo Inc. will enhance its software to give early-access companies backed by tangible assets an easy way to access the token markets. The company's platform will change how people transact real estate, digital assets, crops, and raw materials by allowing companies to access the future value of their assets. The growth of Bitcoin and other cryptocurrencies brings new regulations for large financial service companies, which will require a smart solution to manage their growing portfolios.
About ZenaDrone, Inc. (https://www.zenadrone.com/)
ZenaDrone, Inc. is dedicated to improving its intelligent unmanned aerial vehicle technology, which uses machine learning software and AI. ZenaDrone, Inc. began with the goal of revolutionizing the hemp farming sector and later evolved into an intelligent and multifunctional industrial surveillance, inspection and monitoring solution.
About EmergingGrowth.com
Founded in 2009, EmergingGrowth.com quickly became a leading independent small cap media portal. Over the years, it has developed an extensive history of providing unparalleled content, in identifying emerging growth companies and markets that can be overlooked by the investment community. The next step in its evolution is the Emerging Growth Conference.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in an effective and time efficient manner. The audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All Conferences are first announced on Twitter – Follow us on Twitter
All Conference replays emerge on our YouTube Channel – Subscribe to our YouTube Channel
All sessions are conducted through video webcasts and will take place in the Eastern time zone. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.
If you believe your company, product or service is at the cusp of going mainstream, or you have an idea for an "Emerging Growth" company that might fit our model, contact us here.
This is an advertisement and not an offer or solicitation to buy or sell any securities. All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is not the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks. This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated four thousand five hundred dollars by Epazz, Inc. for distribution of this content. EmergingGrowth.com has also received additional past compensation and EmergingGrowth.com may receive future compensation, details about which can be found in our full disclosure, here, https://emerginggrowth.com/3729-6827465/. You can easily lose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.
CONTACT:
Company: EmergingGrowth.com - http://www.EmergingGrowth.com
Contact Email: info@EmergingGrowth.com
SOURCE: EmergingGrowth.com